Ra Capital Management buys $16,653,067 stake in Aimmune Therapeutics Inc (AIMT)

Aimmune Therapeutics Inc (AIMT) : Ra Capital Management scooped up 502,740 additional shares in Aimmune Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 1,292,940 shares of Aimmune Therapeutics Inc which is valued at $16,653,067.Aimmune Therapeutics Inc makes up approximately 1.93% of Ra Capital Management’s portfolio.

Other Hedge Funds, Including , Price T Rowe Associates Inc Md boosted its stake in AIMT in the latest quarter, The investment management firm added 115,700 additional shares and now holds a total of 604,098 shares of Aimmune Therapeutics Inc which is valued at $7,780,782.Teachers Advisors Inc boosted its stake in AIMT in the latest quarter, The investment management firm added 25,433 additional shares and now holds a total of 42,204 shares of Aimmune Therapeutics Inc which is valued at $543,588.Tlp Group boosted its stake in AIMT in the latest quarter, The investment management firm added 17,000 additional shares and now holds a total of 2,833,285 shares of Aimmune Therapeutics Inc which is valued at $36,747,706. Aimmune Therapeutics Inc makes up approx 22.08% of Tlp Group’s portfolio.Swiss National Bank boosted its stake in AIMT in the latest quarter, The investment management firm added 9,200 additional shares and now holds a total of 31,474 shares of Aimmune Therapeutics Inc which is valued at $389,963. Strs Ohio sold out all of its stake in AIMT during the most recent quarter. The investment firm sold 3,600 shares of AIMT which is valued $43,164.

Aimmune Therapeutics Inc formerly Allergen Research Corporation is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach including the development of proprietary candidates for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products defined treatment protocols and support services. Its lead product AR101 which has completed a Phase II study is designed to treat peanut allergy. The Company’s AR101 is a mixture of naturally occurring proteins and pharmaceutical-grade ingredients. Its CODIT system aims to improve upon oral immunotherapy (OIT) by precisely controlling the amount of food protein administered and establishing very gradual treatment regimens that begin with low doses of protein.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *